Patrizio Caturegli

Associate Professor
Pathology
Johns Hopkins University
United States of America

Doctor Pathology
Biography

Dr. Patrizio P. Caturegli is an associate professor of pathology at the Johns Hopkins University School of Medicine. An immunopathologist, Dr. Caturegli is the director of the Johns Hopkins Hypophysitis Center and serves on the faculty of the Autoimmune Disease Research Center. His clinical and research focus is autoimmune diseases of the endocrine glands. These include myocarditis, thyroiditis, hypophysitis, Sjogren''s syndrome, and complete congenital heart blockage. Dr. Caturegli earned his medical degree from Italy’s Faculty of Medicine E Chirurgua University of Pisa. He completed a residency in endocrinology at the University of Pisa and a residency in pathology at Johns Hopkins. He performed a fellowship in public health at Johns Hopkins where he also earned a M.P.H. from Hopkins’ Bloomberg School of Public Health. He joined the Johns Hopkins faculty in 1999. He is American Board of Pathology-certified in clinical pathology and has published more than 100 journal articles.

Research Intrest

Thyroid peroxidase (TPO); Thyroglobulin; Autoantibodies; Hurthle cell lesions; Congenital complete heart block; Sjogren's syndrome; Hypophysitis; Thyroiditis; Myocarditis; Endocrinology; Pituitary disease; Thyroid disease; Autoimmune disease

List of Publications
Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. "Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody." Sci Transl Med. 2014 Apr 2;6(230):230ra45.
McLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S. "Variation in rates of autoimmune thyroid disease by race/ethnicity in US military personnel." JAMA. 2014 Apr 16;311(15):1563-5.
De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong TD, Santegoets SJ, Slovin SF, Zheng L, Laheru DA, Jaffee EM, Gerritsen WR, van den Eertwegh AJ, Le DT, Caturegli P. "Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival." Int J Cancer. 2014 May 15.